

THE NEXT WAVE  
IN ALPHA-1  
THERAPY

## PROLASTIN®-C LIQUID: #1 prescribed in alpha-1

25  
YEARS

The #1-prescribed alpha-1 therapy every year for more than 25 years  
—in a ready-to-infuse, liquid formulation<sup>1,2</sup>




Experience of over 4 million infusions worldwide<sup>3</sup>



>90% success rate in obtaining coverage and the Assist \$0 copay  
program providing up to \$6600/year for eligible patients<sup>4</sup>



One dedicated coordinator specifically assigned to support you and your  
patients for a seamless transition<sup>4</sup>




Automatic enrollment in an alpha-1 disease-management program  
proven to impact compliance and healthcare utilization<sup>4,5</sup>

## Just 1 step gets your patients started

Please see reverse side for Important Safety Information and refer to  
accompanying full Prescribing Information for PROLASTIN-C LIQUID.

GRIFOLS



## Important Safety Information

PROLASTIN®-C LIQUID is an  $\alpha_1$ -proteinase inhibitor (human) ( $\alpha_1$ -PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of  $\alpha_1$ -PI ( $\alpha_1$ -antitrypsin deficiency).

### Limitations of Use

- The effect of augmentation therapy with any  $\alpha_1$ -PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in  $\alpha_1$ -PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
- Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
- PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe  $\alpha_1$ -PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to  $\alpha_1$ -PI products.


Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

**Please see accompanying full Prescribing Information for PROLASTIN-C LIQUID.**

**References:** 1. Barker A, Campos M, Brantly M, et al. Bioequivalence of a liquid formulation of  $\alpha_1$ -proteinase inhibitor compared with Prolastin®-C (lyophilized  $\alpha_1$ -PI) in  $\alpha_1$ -antitrypsin deficiency. *COPD*. 2017;14(6):590-596. 2. Data on file, Executive Summary, Grifols. 3. Data on file, Grifols. 4. Data on file, PROLASTIN DIRECT program, Grifols. 5. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with  $\alpha_1$ -1 antitrypsin deficiency. *COPD*. 2009;6(1):31-40.



# GRIFOLS